A Phase 3 clinical trial update dated November 5, 2026 reports recruitment underway for a study involving berobenatide (PF-08653944). The trial, registered as NCT07845500, is titled "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity." Its current status is listed as recruiting. The study is designed around people with overweight or obesity who are transitioning to a monthly dosing schedule of berobenatide for weight maintenance purposes. No results have been posted for this trial at this time. The listing does not provide outcome data, efficacy claims, or safety findings beyond confirming the trial's design and current recruiting status. This update pertains to a related compound in the same therapeutic area as tirzepatide, which remains an approved medication. Readers interested in background information on tirzepatide, including its approved uses and mechanism, can consult the compound overview for additional context.
Phase 3 Trial Recruiting for Monthly Berobenatide in Weight Maintenance
See the full tirzepatide overview
Source: https://clinicaltrials.gov/study/NCT07845500